Comment on "Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis"
Epilepsy Behav
.
2022 Mar:128:108550.
doi: 10.1016/j.yebeh.2021.108550.
Epub 2022 Jan 19.
Authors
James Wheless
1
,
Jurriaan Peters
2
,
Sunita N Misra
3
,
Danielle Becker
4
,
Adrian L Rabinowicz
3
,
Joseph Sirven
5
,
Enrique Carrazana
6
Affiliations
1
Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: jwheless@uthsc.edu.
2
Boston Children's Hospital, Boston, MA, USA.
3
Neurelis, Inc., San Diego, CA, USA.
4
Dept of Neurology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
5
Dept of Neurology, Mayo Clinic, Jacksonville, FL, USA.
6
Neurelis, Inc., San Diego, CA, USA; University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
PMID:
35063372
DOI:
10.1016/j.yebeh.2021.108550
No abstract available
Publication types
Letter
Comment
MeSH terms
Administration, Intranasal
Benzodiazepines / therapeutic use
Child
Diazepam* / therapeutic use
Humans
Seizures / drug therapy
Status Epilepticus* / drug therapy
Substances
Benzodiazepines
Diazepam